Enanta Pharmaceuticals (ENTA) Free Cash Flow (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Free Cash Flow of -$7.2 million for Q1 2026, up 38.83% on a QoQ basis from -$11.7 million in Q4 2025, and up 67.97% year-over-year from -$4.3 million in Q1 2025.
Enanta Pharmaceuticals (ENTA) Free Cash Flow (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Free Cash Flow history runs 15 years deep, the most recent figure standing at -$7.2 million for Q1 2026.
- Quarterly Free Cash Flow rose 67.97% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 104.95% YoY) and the FY2025 annual result came in at -$19.3 million, up 77.16% from the prior year.
- Free Cash Flow was -$7.2 million for Q1 2026 at Enanta Pharmaceuticals, up from -$11.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $17.4 million in Q2 2025 and bottomed at -$38.2 million in Q2 2023.
- A 5-year average of -$17.6 million and a median of -$17.2 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 462.82% — and 2025, when it soared 253.75%.
- Enanta Pharmaceuticals' Free Cash Flow stood at -$35.6 million in 2022, then advanced by 28.56% to -$25.5 million in 2023, then advanced by 24.5% to -$19.2 million in 2024, then jumped by 39.16% to -$11.7 million in 2025, then jumped by 38.83% to -$7.2 million in 2026.
- Business Quant data shows ENTA's Free Cash Flow at -$7.2 million in Q1 2026, -$11.7 million in Q4 2025, and $4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | -7.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.16 Mn |
| Mar 31, 2026 | -7.16 Mn |
| Dec 31, 2025 | -11.70 Mn |
| Dec 31, 2025 | -11.70 Mn |
| Sep 30, 2025 | 4.95 Mn |
| Sep 30, 2025 | 4.95 Mn |
| Jun 30, 2025 | 17.35 Mn |
| Jun 30, 2025 | 17.35 Mn |
| Mar 31, 2025 | -22.34 Mn |
| Mar 31, 2025 | -22.34 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -16.70 Mn |
| Sep 30, 2024 | -16.70 Mn |
| Jun 30, 2024 | -11.29 Mn |
| Jun 30, 2024 | -11.29 Mn |
| Mar 31, 2024 | -30.91 Mn |
| Mar 31, 2024 | -30.91 Mn |
| Dec 31, 2023 | -25.47 Mn |
| Dec 31, 2023 | -25.47 Mn |